Dr. James A. Wallace
Claim this profileIngalls Memorial Hospital
Studies Cancer
Studies Lung Cancer
10 reported clinical trials
42 drugs studied
Area of expertise
1Cancer
Stage IV
Stage III
Stage II
2Lung Cancer
Stage IV
Stage III
EGFR positive
Affiliated Hospitals
Clinical Trials James A. Wallace is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Immunotherapy +/− Targeted Therapy
for Nasopharyngeal Cancer
This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for which no treatment is currently available (incurable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving immunotherapy with nivolumab and ipilimumab and targeted therapy with cabozantinib may help shrink and stabilize nasopharyngeal cancer.
Recruiting1 award Phase 2
More about James A. Wallace
Clinical Trial Related3 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments James A. Wallace has experience with
- Carboplatin
- Cisplatin
- Bevacizumab
- Pembrolizumab
- Pemetrexed
- Atezolizumab
Breakdown of trials James A. Wallace has run
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Recurrence
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does James A. Wallace specialize in?
James A. Wallace focuses on Cancer and Lung Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is James A. Wallace currently recruiting for clinical trials?
Yes, James A. Wallace is currently recruiting for 7 clinical trials in Harvey Illinois. If you're interested in participating, you should apply.
Are there any treatments that James A. Wallace has studied deeply?
Yes, James A. Wallace has studied treatments such as Carboplatin, Cisplatin, Bevacizumab.
What is the best way to schedule an appointment with James A. Wallace?
Apply for one of the trials that James A. Wallace is conducting.
What is the office address of James A. Wallace?
The office of James A. Wallace is located at: Ingalls Memorial Hospital, Harvey, Illinois 60426 United States. This is the address for their practice at the Ingalls Memorial Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.